Portal de investigación
RMC-6291-101 Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
REVOLUTION MEDICINES, INC.
Cita
RMC-6291-101 Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors. (RMC-6291-101). Revolution Medicines, Inc. 2024IP:FRANCISCO DE ASÍS APARISI APARISI.